^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HR negative

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Entrez ID:
2d
Prognostic implications of HER2NEU-low in metastatic breast cancer. (PubMed, Cancer Med)
In the largest such analysis performed to date, our study demonstrates a small but statistically significant association with improved survival for HER2-low tumors compared to HER2-negative tumors in MBC.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative
13d
High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer. (PubMed, Cancers (Basel))
In HER2-negative BC, the CD163+ TAM count was not significantly associated with survival. These results suggest that a high CD163+ TAM count predicts an inferior outcome, especially in HER2+ BC patients, and as adjuvant trastuzumab did not overcome the poor prognostic effect, combination treatments including therapies targeting the macrophage function could represent an effective therapeutic approach in HER2+ BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
HR positive • HER-2 negative • HR negative
|
Herceptin (trastuzumab)
14d
ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features. (PubMed, J Pathol Clin Res)
ERBB2-amplified ILBC is a distinct molecular subgroup with frequent coamplification of CDK12, whereas ERBB2 sequence mutations occur only in ERBB2-unamplified ILBC. CDK12/ERBB2 co-amplification may explain the poor prognosis and therapy resistance of ERBB2-amplified ILBC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CDK12 (Cyclin dependent kinase 12) • CDH1 (Cadherin 1) • SOX10 (SRY-Box 10)
|
HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 negative • HR negative • CDK12 mutation • CDH1 mutation • CDK12 amplification
17d
Age-related phenotypes in breast cancer: A population-based study. (PubMed, Int J Cancer)
We point to aggressive phenotypes and increased tumor cell proliferation in breast cancer of the young. Hence, tumors of young breast cancer patients may present unique biological features, also when accounting for screen/interval differences, that may open for new clinical opportunities, stratifying treatment by age.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative
19d
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. (PubMed, Eur J Cancer)
immune spatial classification on immune cells infiltrates seems crucial and could help patients' selection in clinical trial and greatly improve responses to specific therapies.
Journal • Immune cell
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
HR negative
|
cyclophosphamide • methotrexate
22d
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel (clinicaltrials.gov)
P2, N=49, Active, not recruiting, Consorzio Oncotech | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 negative • HR negative
|
VENTANA PD-L1 (SP142) Assay
|
Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
24d
NRG-BR005: Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery (clinicaltrials.gov)
P2, N=175, Suspended, NRG Oncology | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
Trial completion date • Trial primary completion date • Surgery • Biopsy
|
PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR negative
26d
Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI. (PubMed, Br J Radiol)
A nomogram incorporating MRI and US with clinicopathologic variables was developed to provide a brief and concise approach in predicting pCR to assist clinicians in making treatment decisions early.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative • EGFR positive
1m
Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments. (PubMed, BMC Cancer)
Guidance on tailored precision therapy with consideration of genomic mutations was possible for some patients with information provided by F1CDx. Clinicians should consider using F1CDx at turning points in the course of the disease.
Journal • Tumor mutational burden • PARP Biomarker • BRCA Biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • CDH1 (Cadherin 1)
|
BRCA2 mutation • HR positive • PIK3CA mutation • PTEN mutation • HR negative
|
FoundationOne® CDx • FoundationOne® Liquid CDx
1m
Predictive factors for complete pathological response in hormone receptor-negative breast cancer patients undergoing neoadjuvant chemotherapy. (PubMed, Pathol Res Pract)
In conclusion, hormone receptor-negative breast tumors stand to benefit from increased pCR rates if they encompass a DCIS component and exhibit CD10 expression while lacking EGFR expression. These findings underscore the importance of comprehensive profiling in predicting pCR outcomes in hormone receptor-negative breast cancer patients undergoing neoadjuvant chemotherapy.
Journal
|
EGFR (Epidermal growth factor receptor) • MME (Membrane Metalloendopeptidase)
|
EGFR expression • HR negative
2ms
Enrollment open • Metastases
|
HER-2 positive • HR positive • HR negative
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
2ms
Trial completion
|
HR positive • HR negative
|
letrozole • anastrozole • exemestane
2ms
Androgen Receptor Expression in ER and PR Negative Breast Cancer-A Study from a Tertiary Hospital in Northern India. (PubMed, South Asian J Cancer)
Conclusion  Our study shows that significant proportion of ER and PR Negative breast carcinomas (ER- PR- Her2+ and TNBCs) show AR expression. We strongly recommend routine evaluation of all hormone receptor-negative breast carcinomas for AR status by immunohistochemistry.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 overexpression • HR negative • AR expression • PGR negative
2ms
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment (clinicaltrials.gov)
P=N/A, N=10, Suspended, Laura Kennedy | Trial completion date: Dec 2024 --> Aug 2025 | Recruiting --> Suspended | Trial primary completion date: Dec 2023 --> Aug 2024
Trial completion date • Trial suspension • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HR negative
2ms
Impact of neoadjuvant chemotherapy on breast cancer-related lymphedema after axillary lymph node dissection: a retrospective cohort study. (PubMed, Breast Cancer Res Treat)
NAC receipt has a statistically significant increase in BCRL risk in patients with ALND. These patients should be closely monitored and may benefit from early BCRL intervention.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HR negative
3ms
The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion. (PubMed, Am J Cancer Res)
HMGB3 plays an oncogenic function and contributes to the development of LVI in BC. Results warrant further investigation as a potential target to inhibit LVI in BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative
3ms
The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study. (PubMed, Cureus)
This study suggests an unlikely add-on effect of an anthracycline-based regimen for NAC in HER2-positive breast cancer. Moreover, our results support that the pCR rate is high in patients with hormone receptor-negative, HER2-positive breast cancer.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative • HR negative + HER-2 positive
|
Herceptin (trastuzumab) • 5-fluorouracil • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
3ms
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer (clinicaltrials.gov)
P3, N=250, Not yet recruiting, Daiichi Sankyo, Inc. | Phase classification: P3b --> P3 | Initiation date: Oct 2023 --> Dec 2023
Phase classification • Trial initiation date • Metastases
|
HER-2 positive • HR positive • HR negative
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
3ms
Increased Expression of the ABCA1 and ABCA3 Transporter Genes is Associated with Cisplatin Resistance in Breast Cancer Cells. (PubMed, Asian Pac J Cancer Prev)
Experiments with cytotoxicity assays demonstrate that higher expression of ABCA1 and ABCA3 in AMJ13 and MCF-7 breast cancer cell lines is linked to their resistance.   The findings of this study suggest that the ABCA1 and ABCA3 transporters play a significant role in the resistance to cisplatin and,.
Journal
|
ABCA1 (ATP Binding Cassette Subfamily A Member 1) • ABCA3 (ATP Binding Cassette Subfamily A Member 3)
|
HR positive • HR negative
|
cisplatin
3ms
Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects. (PubMed, JCI Insight)
In vitro and in vivo patient-derived xenograft experiments revealed that pretreatment of the TKR subgroup with a tyrosine kinase inhibitor (lapatinib or tucatinib) could inhibit HER2 signaling and induce accumulated expression of nonfunctional HER2, resulting in increased sensitivity to the sequential HER2-targeting, Ab-drug conjugate DS-8201. Our findings identify clinically relevant subgroups and provide potential therapeutic strategies for HER2-low TNBC subtypes.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HR negative
|
lapatinib • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)
3ms
Hypomethylation of DRD2 promotes breast cancer through the FLNA-ERK pathway. (PubMed, Cancer Genet)
This study demonstrated the DRD2 promoter region is hypomethylated in hormone-receptor-negative breast cancer or with high-risk factors. The methylation status of the DRD2 promoter and FLNA-ERK signaling pathway and the DRD2 expression in breast cancer treatment need to be considered.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • DRD2 (Dopamine Receptor D2)
|
HR negative • CD31 expression • DRD2 expression
4ms
Classification of HER2-negative breast cancers by ERBB2 copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations. (PubMed, Ther Adv Med Oncol)
Classification of HER2-negative BCs according to ERBB2 CNA status reveals differences in the genomic landscape. The implications of concurrent aberrations in other genes on chromosome 17 merit further research in ERBB2 non-neutral BCs.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • NF1 (Neurofibromin 1) • NCOR1 (Nuclear Receptor Corepressor 1) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
|
HR positive • HER-2 amplification • HER-2 negative • HER-2 expression • HR negative
4ms
A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (SABCS 2023)
This multi-center, single arm, phase 2 study is currently evaluating the impact of cryo with standard-of-care pembrolizumab (pembro) in women with residual TNBC after taxane-based NAC, a group at high risk of early relapse (NCT03546686)...Adjuvant capecitabine or olaparib is recommended for all patients per local standard-of-care...Secondary endpoints include Invasive Disease-Free Survival (IDFS), Distant Disease-Free Survival (DDFS), overall survival (OS) and safety. Exploratory correlative studies will be performed on tumor and serum to characterize the immunologic impact of the intervention and to explore predictors of efficacy and toxicity
Clinical • P2 data • Checkpoint inhibition
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HR negative
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine
4ms
HER2-low Status among Patients with Li-Fraumeni Syndrome and Breast Cancer (SABCS 2023)
Contrary to our initial hypothesis, the frequency of HER2-low status in this cohort of LFS patients with breast cancer was lower than anticipated. These results suggest that while breast cancer developing in the context of germline TP53 variants appears to be associated with HER2 amplification, it does not impact lower expressions of HER2. This observation reinforces the concept that HER2-low status does not seem to play a significant role as a driver of tumorigenesis.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HR negative • HR positive + HER-2 negative • PTEN mutation + HR positive
4ms
MHC Class I and II Expression, Functional Tertiary Lymphoid Structure (TLS), and Outcomes in Early-Stage HER2-Positive (HER2+) Breast Cancer in NCCTG N9831 (Alliance) (SABCS 2023)
A greater number of LA was associated with improved outcomes in pts with early-stage HER2+ breast cancer, particularly when treated with chemotherapy alone. Using histologic and genomic integration with the combination of pathological LA and TLS-related immune genes, we identified that pts with functional TLS with LA ≥ 1 and higher expression of BCL6 or IL21R had significantly improved outcomes when treated with trastuzumab. High MHC class I and II expressions are associated with the presence of functional TLS, underscoring the crucial role of antigen presentation in the generation of an effective adaptive immune response.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • CD200 (CD200 Molecule) • ICOSLG (Inducible T Cell Costimulator Ligand) • TBX21 (T-Box Transcription Factor 21) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL1R1 (Interleukin 1 receptor, type I) • IL21 (Interleukin 21) • IL21R (Interleukin 21 Receptor)
|
HER-2 positive • HR negative
|
Herceptin (trastuzumab)
4ms
Clinical-pathological determinant factors to choose between four or six cycles of adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) in a retrospective real-world cohort of HER2-negative breast cancer patients. (SABCS 2023)
Docetaxel plus cyclophosphamide (TC) has replaced doxorubicin plus cyclophosphamide (AC) for lower-risk patients that need adjuvant chemotherapy. TC6 was commonly used for patients with unfavorable prognostic factors as history of previous breast cancer, (IDC), HG III, lymph node positive and stage II. Patients who received TC6 had less chance of completing the treatment and more severe toxicity, especially late peripheral neuropathy. There was no difference in DFS or OS.
Retrospective data • Real-world evidence • BRCA Biomarker • Real-world
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
|
HR positive • HER-2 negative • HR negative • BRCA mutation
|
docetaxel • doxorubicin hydrochloride • cyclophosphamide
4ms
A phase II study of nivolumab plus ipilimumab and androgen receptor antagonist bicalutamide to stimulate thymic T cell generation in HER2-negative metastatic breast cancer (SABCS 2023)
The regimen of ipilimumab, nivolumab, plus bicalutamide is safe and clinically active in 1st/2nd-line HER2-negative MBC. Neither cohort crossed the Simon futility barrier for cohort expansion, however durable responses were observed including in PD-L1-negative patients, highlighting the unmet need for biomarkers to identify candidates for chemotherapy-sparing checkpoint blockade. Further research is indicated to evaluate the impact of AR antagonists on T-cell function and thymic stimulation in MBC.
P2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
HER-2 negative • PD-L1 negative • HR negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • bicalutamide
4ms
Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer (SABCS 2023)
149 (86.6%) patients were treated with paclitaxel or nab-paclitaxel, 20 (11.6%) patients were treated with docetaxel, and 3 patients (1.7%) were treated with vinorelbine. Nearly half of patients with de novo HER2+ MBC have CR on first-line chemotherapy and HP; patients with CR have significantly longer PFS compared to patients with non-CR. Future studies evaluating treatment discontinuation following durable CR and the utility of circulating tumor DNA in this setting are needed.
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HR negative • EGFR positive
|
Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • albumin-bound paclitaxel • vinorelbine tartrate
4ms
Novel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling (SABCS 2023)
We present novel metrics of HER2 heterogeneity via HDmIF, which offer detailed characterization of the diversity of HER2 expression in a large, clinically-annotated cohort with long-term follow-up. Identification of a strong association between immunophenotype and RFS supports further investigation of the highly immune activated subsets of ER-/HER2+ breast cancer. Strong correspondence of HER2 IF and IHC and our HAIQu methodology offers a pathway to translation of HER2het metrics to clinical practice.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 positive • HER-2 expression • PD-L1 underexpression • HR negative • ERBB3 expression • PD-1-L • PD-L1-L
4ms
Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study (SABCS 2023)
In this global study, 1 out of 5 young BRCA carriers conceived within 10 years after a BC diagnosis, higher than rates previously reported in unselected young BC populations. Pregnancy following BC in BRCA carriers did not appear to adversely impact maternal prognosis or fetal outcomes. These findings should be incorporated into oncofertility counseling of young BRCA carriers with BC.
Clinical • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
HR negative
4ms
Programmed Death-Ligand 1 and Receptor Tyrosine Kinases in Breast Cancer (SABCS 2023)
The TKIs crizotinib [a MET inhibitor] and gefitinib [an EGFR inhibitor] were used as a single treatment and in combination with the cytokines; tumor necrosis factor-α (TNF-α) or interferon-γ (INF-γ) in MCF7 and MDA-MB-231 breast cancer cells in vitro. The co-expression of the PD-L1 gene with MET and EGFR genes in breast cancer was associated with advanced disease presentation and worse prognosticators in patients. Together, TKIs that target MET or EGFR could be an appealing therapeutic target in breast cancer, particularly in younger patients with the non-luminal disease.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
|
PD-L1 expression • HER-2 positive • HR negative • MET expression • PD-L1-L
|
Xalkori (crizotinib) • gefitinib
4ms
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized,phase 3 trial (SABCS 2023)
In neoadjuvant treatment of HER2-positive EBC, 18 weeks of nab-paclitaxel monotherapy combined with dual HER2 blockade has shown significantly higher pCR rates and improved tolerability compared to the standard docetaxel plus carboplatin and dual HER2 blockade regimen. These findings could potentially reshape preferences for neoadjuvant therapy in HER2-positive EBC. Patient Characteristics pCR by clinical-pathological variables Abbreviation:Nab-PHP,nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab; TCbHP,docetaxel plus carboplatin ,trastuzumab and pertuzumab; HR,hormone receptor; IHC,immunohistochemistry.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HR negative • PGR positive • PGR negative
|
Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • albumin-bound paclitaxel
4ms
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study. (PubMed, BMJ)
The association of DCIS size and margin status with ipsilateral invasive breast cancer and ipsilateral DCIS was small. When these two factors were added to other known risk factors in multivariable models, clinicopathological risk factors alone were found to be limited in discriminating between low and high risk DCIS.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative • EGFR positive
4ms
A-Brave: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (clinicaltrials.gov)
P3, N=474, Active, not recruiting, Istituto Oncologico Veneto IRCCS | Trial completion date: Jun 2023 --> Oct 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
Trial completion date • Trial primary completion date • IO Companion diagnostic • PD(L)-1 companion diagnostic
|
HER-2 (Human epidermal growth factor receptor 2)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • HR negative
|
Bavencio (avelumab)
4ms
Relationship Between Metabolic Activity, Cellularity, Histopathological Features of Primary Tumors and Distant Metastatic Potential in Breast Cancer. (PubMed, Mol Imaging Radionucl Ther)
Primary tumors with higher metabolic-glycolytic activity and higher cellularity were more aggressive and had higher metastatic potential in breast IDC. Compared with histopathological parameters alone, the combination of imaging parameters and histopathological features of primary tumors may help to better understand tumor biology and behavior.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR negative • EGFR positive
4ms
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 positive • HR positive • HR negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Herceptin (trastuzumab) • Tecentriq (atezolizumab) • vinorelbine tartrate
4ms
Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov)
P1/2, N=40, Completed, ImmuneSensor Therapeutics Inc. | Recruiting --> Completed | N=115 --> 40 | Trial completion date: Dec 2023 --> Sep 2023
Trial completion • Enrollment change • Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
HR negative
|
IMSA101
5ms
New trial
|
HR positive • HR negative
5ms
The Role of Tumor Bed Boost in Breast Cancer Patients with HER2-Positive Disease Treated with Breast Conservation Therapy. (PubMed, Int J Radiat Oncol Biol Phys)
A tumor bed boost is commonly implemented in HER2-positive breast cancer patients undergoing breast-conserving surgery and adjuvant radiation. This data supports previous retrospective and post-hoc trial analyses in omitting the tumor bed boost and treating patients who will receive adjuvant systemic therapy with whole breast radiation alone, provided that the patient receives HER2-directed therapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HR negative
5ms
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel (clinicaltrials.gov)
P2; Trial primary completion date: Jul 2022 --> Jul 2024
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 negative • HR negative
|
VENTANA PD-L1 (SP142) Assay
|
Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
5ms
Breast cancer radiation therapy: Current questions in 2023 (PubMed, Cancer Radiother)
The main risk factors for local recurrence are young age, the associated extended ductal in situ component, hormone receptor negative and high-grade status. The results of the simultaneous integrated boost (SIB) seem similar with normo- or moderately hypofractionated radiation therapy regimen.
Review • Journal
|
HR negative
6ms
Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer. (PubMed, Eur J Cancer)
Temporal heterogeneity of HER2-low expression is observed in substantial numbers of post-NAC breast cancer patients. Clinical outcomes show no significant associations, except in the post-therapeutic HER2-low, hormone receptor negativity subset. The prognostic implications of HER2 transition in HER2-low breast cancer require further investigation.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 expression • HER-2 underexpression • HR negative • ER negative